Foghorn Therapeutics (FHTX) vs. Its Rivals Financial Comparison

Foghorn Therapeutics (NASDAQ:FHTX) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Foghorn Therapeutics to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, risk, profitability, earnings and valuation.

Profitability

This table compares Foghorn Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
Foghorn Therapeutics Competitors	-9,054.31%	-198.21%	-30.53%

Insider & Institutional Ownership

61.5% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Foghorn Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics’ rivals have a beta of 1.02, indicating that their average stock price is 2% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Foghorn Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1	6	4	0	2.27
Foghorn Therapeutics Competitors	9770	15029	45237	1570	2.54

Foghorn Therapeutics currently has a consensus target price of $6.14, indicating a potential upside of 195.33%. As a group, “Biotechnology” companies have a potential upside of 95.46%. Given Foghorn Therapeutics’ higher probable upside, equities research analysts plainly believe Foghorn Therapeutics is more favorable than its rivals.

Earnings & Valuation

This table compares Foghorn Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Foghorn Therapeutics	$36.74 million	-$74.28 million	-2.12
Foghorn Therapeutics Competitors	$737.75 million	$13.23 million	-10.05

Foghorn Therapeutics’ rivals have higher revenue and earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Foghorn Therapeutics rivals beat Foghorn Therapeutics on 7 of the 13 factors compared.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.